Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13770
Country/Region: Ethiopia
Year: 2018
Main Partner: Harari Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $300,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $30,000
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $30,000
Care: Pediatric Care and Support (PDCS) $12,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $12,000
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $198,000
Treatment: Pediatric Treatment (PDTX) $18,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 54
HTS_SELF 10-14, Female, Directly-Assisted 2019 4
HTS_SELF 10-14, Male, Directly-Assisted 2019 4
HTS_SELF 15-19, Female, Directly-Assisted 2019 4
HTS_SELF 15-19, Male, Directly-Assisted 2019 4
HTS_SELF 20-24, Female, Directly-Assisted 2019 6
HTS_SELF 20-24, Male, Directly-Assisted 2019 6
HTS_SELF 25-29, Female, Directly-Assisted 2019 4
HTS_SELF 25-29, Male, Directly-Assisted 2019 4
HTS_SELF 30-34, Female, Directly-Assisted 2019 4
HTS_SELF 30-34, Male, Directly-Assisted 2019 4
HTS_SELF 35-39, Female, Directly-Assisted 2019 2
HTS_SELF 35-39, Male, Directly-Assisted 2019 2
HTS_SELF 40-49, Female, Directly-Assisted 2019 2
HTS_SELF 40-49, Male, Directly-Assisted 2019 4
HTS_SELF Directly-Assisted 2019 54
HTS_TST <5, Unknown Sex, Negative 2019 61
HTS_TST 20-24, Female, Negative 2019 1
HTS_TST 25-29, Female, Negative 2019 38
HTS_TST 25-29, Female, Negative 2019 2
HTS_TST 25-29, Female, Negative 2019 26
HTS_TST 25-29, Male, Negative 2019 20
HTS_TST 25-29, Male, Negative 2019 26
HTS_TST 30-34, Female, Negative 2019 5
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 26
HTS_TST 30-34, Male, Negative 2019 11
HTS_TST 30-34, Male, Negative 2019 1
HTS_TST 30-34, Male, Negative 2019 26
HTS_TST 35-39, Female, Negative 2019 13
HTS_TST 35-39, Female, Negative 2019 5
HTS_TST 35-39, Female, Negative 2019 14
HTS_TST 35-39, Male, Negative 2019 12
HTS_TST 35-39, Male, Negative 2019 2
HTS_TST 35-39, Male, Negative 2019 14
HTS_TST 40-49, Female, Negative 2019 11
HTS_TST 40-49, Female, Negative 2019 14
HTS_TST 40-49, Male, Negative 2019 13
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 13
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 983
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 79
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 129
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 186
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 8
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 11
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 11
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 5
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 27
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 5
HTS_TST_POS <5, Unknown Sex, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 2
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 264
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 264
PMTCT_ART Already on ART at beginning of current pregnancy 2019 69
PMTCT_ART New on ART 2019 29
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 98
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 94
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 24
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 118
PMTCT_EID Sum of Infant Age disaggregates 2019 118
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 24
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 27
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 53
TB_PREV By Age/Sex (Numerator): <15, Female 2019 58
TB_PREV By Age/Sex (Numerator): <15, Male 2019 58
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 530
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 527
TB_PREV IPT, Life-long ART, Already, Positive 2019 975
TB_PREV IPT, Life-long ART, New, Positive 2019 198
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,173
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,204
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 60
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 60
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 542
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 542
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 1,000
TB_PREV_den IPT, Life-long ART, New, Positive 2019 204
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 13
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 127
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 14
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 165
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 319
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 323
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 13
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 128
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 14
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 168
TX_CURR 25-29, Female, Positive 2019 133
TX_CURR 25-29, Female, Positive 2019 3
TX_CURR 25-29, Male, Positive 2019 57
TX_CURR 25-29, Male, Positive 2019 1
TX_CURR 30-34, Female, Positive 2019 389
TX_CURR 30-34, Female, Positive 2019 8
TX_CURR 30-34, Male, Positive 2019 110
TX_CURR 30-34, Male, Positive 2019 2
TX_CURR 35-39, Female, Positive 2019 358
TX_CURR 35-39, Female, Positive 2019 7
TX_CURR 35-39, Male, Positive 2019 130
TX_CURR 35-39, Male, Positive 2019 3
TX_CURR 40-49, Female, Positive 2019 831
TX_CURR 40-49, Female, Positive 2019 16
TX_CURR 40-49, Male, Positive 2019 12
TX_CURR 40-49, Male, Positive 2019 591
TX_CURR Age/Sex: <1 2019 4
TX_CURR Age/Sex: <1-9 2019 63
TX_CURR Age/Sex: 1-9 2019 1
TX_CURR Age/Sex: 10-14 Female 2019 142
TX_CURR Age/Sex: 10-14 Female 2019 2
TX_CURR Age/Sex: 10-14 Male 2019 142
TX_CURR Age/Sex: 10-14 Male 2019 2
TX_CURR Age/Sex: 15-19 Female 2019 146
TX_CURR Age/Sex: 15-19 Female 2019 3
TX_CURR Age/Sex: 15-19 Male 2019 118
TX_CURR Age/Sex: 15-19 Male 2019 2
TX_CURR Age/Sex: 20-24 Female 2019 178
TX_CURR Age/Sex: 20-24 Female 2019 3
TX_CURR Age/Sex: 20-24 Male 2019 121
TX_CURR Age/Sex: 20-24 Male 2019 2
TX_CURR Age/Sex: 50+ Female 2019 559
TX_CURR Age/Sex: 50+ Female 2019 11
TX_CURR Age/Sex: 50+ Male 2019 332
TX_CURR Age/Sex: 50+ Male 2019 6
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 4,404
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 84
TX_CURR Sum of age/sex disaggregates 2019 264
TX_CURR Sum of Age/Sex disaggregations 2019 5
TX_NEW 25-29, Female, Positive 2019 3
TX_NEW 25-29, Female, Positive 2019 1
TX_NEW 25-29, Male, Positive 2019 1
TX_NEW 30-34, Female, Positive 2019 7
TX_NEW 30-34, Female, Positive 2019 2
TX_NEW 30-34, Male, Positive 2019 5
TX_NEW 30-34, Male, Positive 2019 1
TX_NEW 35-39, Female, Positive 2019 5
TX_NEW 35-39, Female, Positive 2019 2
TX_NEW 35-39, Male, Positive 2019 2
TX_NEW 35-39, Male, Positive 2019 1
TX_NEW 40-49, Female, Positive 2019 15
TX_NEW 40-49, Female, Positive 2019 4
TX_NEW 40-49, Male, Positive 2019 13
TX_NEW 40-49, Male, Positive 2019 3
TX_NEW By Age/Sex: 1-9 2019 9
TX_NEW By Age/Sex: 1-9 2019 1
TX_NEW By Age/Sex: 10-14 Female 2019 13
TX_NEW By Age/Sex: 10-14 Female 2019 1
TX_NEW By Age/Sex: 10-14 Male 2019 4
TX_NEW By Age/Sex: 15-19 Male 2019 1
TX_NEW By Age/Sex: 20-24 Female 2019 1
TX_NEW By Age/Sex: 20-24 Male 2019 1
TX_NEW By Age/Sex: 50+ Female 2019 5
TX_NEW By Age/Sex: 50+ Female 2019 2
TX_NEW By Age/Sex: 50+ Male 2019 2
TX_NEW By Age/Sex: 50+ Male 2019 1
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 87
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 19
TX_NEW Sum of Age/Sex disaggregates 2019 27
TX_NEW Sum of Age/Sex disaggregates 2019 4
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 4,045
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 80
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 89
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,953
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 344
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 1,306
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 231
TX_PVLS_den Denominator: Indication: Routine 2019 3,428
TX_PVLS_den Denominator: Indication: Targeted 2019 617
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 11
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 11
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 236
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 127
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 385
TX_RET Numerator by Status: Breastfeeding 2019 4
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 416
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 12
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 11
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 255
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 138
TX_RET_den Denominator by Status: Breastfeeding 2019 4
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 3,842
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 51
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 1
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 23
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 26
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 115
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 115
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 1,807
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 1,805
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 154
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 38
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 192
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 3,265
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 347
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 192
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 38
Cross Cutting Budget Categories and Known Amounts Total: $160,560
Gender: Gender Based Violence (GBV) $10,560
GBV Prevention
Human Resources for Health $150,000